About the job
Revolution Medicines is a pioneering clinical-stage precision oncology firm dedicated to innovating targeted therapies aimed at disrupting key targets in RAS-dependent cancers. Our robust R&D pipeline includes RAS(ON) Inhibitors designed to combat various oncogenic variants of RAS proteins, alongside RAS Companion Inhibitors for synergistic treatment approaches. As part of the Revolution Medicines team, you will collaborate with other passionate individuals committed to making a difference for patients battling cancers linked to mutations in the RAS signaling pathway.
The Opportunity:
As the Executive Medical Director for Gastrointestinal Oncology in Europe, reporting directly to the VP of Medical Affairs, you will lead the strategic medical vision for the GI oncology portfolio across the European market. This pivotal role involves crafting and implementing the regional medical strategy that aligns with our global objectives, ensuring scientific integrity, a focus on patient needs, and adherence to compliance standards. You will serve as a crucial medical partner to global teams, regional leadership, and external stakeholders, acting as a medical authority in GI Oncology. A major aspect of this role will be preparing for and facilitating upcoming product launches, collaborating closely with cross-functional teams, including Commercial, Market Access, Regulatory, Clinical Development, and Global Medical Affairs. This position requires a highly collaborative leader capable of thriving in a matrix environment, influencing without direct authority, and building robust partnerships to ensure compliant and successful product launches.